Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12864408 | 0.82 | POLB (0.62) | DAOALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL605730 | 0.81 | HRH4 (0.60) | DAO | |
| SCHEMBL12864399 | 0.81 | DAO (0.59) | DAOALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL27300769 | 0.80 | HRH4 (0.71) | ALDH1A1KMT2AMEN1TSHRUSP2 | |
| SCHEMBL2735943 | 0.75 | HRH4 (0.70) | ALDH1A1KMT2AMEN1TSHRMAPT | |
| SCHEMBL679809 | 0.72 | DAO (1.00) | DAOALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL25505720 | 0.71 | HRH4 (0.64) | KMT2AMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1171650 | 0.71 | DAO (0.96) | DAOALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL24711247 | 0.71 | ALDH1A1 (0.77) | ALDH1A1KMT2AMEN1TSHRUSP2 | |
| SCHEMBL12864401 | 0.70 | DAO (0.52) | DAOALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2011017634-A2 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACORE INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010017418-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | DAO 2/4885ALDH1A1 350/4885KMT2A 1503/4885 |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | DAO 2/4885ALDH1A1 350/4885KMT2A 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.